Vimarsana
Biggest News Aggregation in the World

Page 2 - Medication Guide News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Medication Guide. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Medication Guide Today - Breaking & Trending Today

Idorsia Pharmaceuticals Ltd: Idorsia announces financial results for the first quarter 2024 - advancing the company with renewed vigor - Vimarsana News

Idorsia Pharmaceuticals Ltd: Idorsia announces financial results for the first quarter 2024 - advancing the company with renewed vigor

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland - May 21, 2024 Idorsia Ltd (SIX: IDIA) today announced its financial results for the first quarter of 2024. Business highlights Viatris

AbbVie Presents New Data Supporting Leading Gastroenterology Portfolio at 2024 Digestive Disease Week® - Vimarsana News

AbbVie Presents New Data Supporting Leading Gastroenterology Portfolio at 2024 Digestive Disease Week®

- AbbVie will present 15 abstracts, including three oral presentations, in Crohn's disease and ulcerative colitis reinforcing AbbVie's commitment to advancing...

New Four-Year Sotyktu (deucravacitinib) Data Demonstrate Durable Response Rates and Consistent Safety in Moderate-to-Severe Plaque Psoriasis - Vimarsana News

New Four-Year Sotyktu (deucravacitinib) Data Demonstrate Durable Response Rates and Consistent Safety in Moderate-to-Severe Plaque Psoriasis

Following four years of continuous Sotyktu treatment, clinical response was maintained in more than seven out of 10 patients for Psoriasis Area and Severity Index 75 in the POETYK PSO long-term...

Valneva Reports First Quarter 2024 Financial Results and Provides Corporate Updates - Vimarsana News

Valneva Reports First Quarter 2024 Financial Results and Provides Corporate Updates

Valneva Reports First Quarter 2024 Financial Results and Provides Corporate Updates Q1 financial highlights Total revenues of €32.8 million, including sales of €32.1...

The U.S. Food & Drug Administration (FDA) Approves Updated LUPKYNIS® (voclosporin) Label to include Long-Term Data from the AURORA Clinical Program - Vimarsana News

The U.S. Food & Drug Administration (FDA) Approves Updated LUPKYNIS® (voclosporin) Label to include Long-Term Data from the AURORA Clinical Program

New data showing sustained complete renal response with LUPKYNIS through three years Monthly kidney function assessment no longer required after first year…